Medclair (MCLR) Q4 2025 earnings summary

Executive summary

• Achieved breakthrough year with net sales rising to 52.1 MSEK and net income to 4.7 MSEK for 2025, confirming successful strategy and readiness for global leadership.

• Strong order intake of 73.2 MSEK for the year, with Q4 order intake at 23.6 MSEK, reflecting robust demand and improved delivery capabilities.

• Expanded international presence with new partnerships and installations in Belgium, UAE, Italy, Germany, Denmark, Qatar, and France.

• Launched new product EXPO.p and e-commerce platform to drive scalable growth, especially in the dental segment.

Financial highlights

• Q4 net sales increased to 10.1 MSEK from 4.4 MSEK year-over-year; full-year net sales rose to 52.1 MSEK from 32.2 MSEK.

• Q4 EBITDA was -0.6 MSEK (0.2 MSEK prior year); full-year EBITDA reached 11.2 MSEK (-0.2 MSEK prior year).

• Q4 net income was -2.2 MSEK (-1.6 MSEK prior year); full-year net income was 4.7 MSEK (-0.7 MSEK prior year).

• Earnings per share for 2025 were 0.06 SEK (-0.01 SEK prior year).

• Cash flow from operations for the year was 7.0 MSEK (3.2 MSEK prior year); cash at year-end was 5.7 MSEK (2.6 MSEK prior year).

Outlook and guidance

• Anticipates continued global demand growth, driven by stricter regulations and sustainability focus.

• Dental segment and select geographies identified as key growth drivers.

• Strategic shift to direct sales in Tier 1 markets to accelerate sales cycles and improve margins.